ADXN
Addex Therapeutics Ltd
There isn't enough reported data to score ADXN yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ADXN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
ADXN's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ADXN PE Valuation
ADXN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ADXN Forward outlook
There aren't enough analyst estimates for ADXN to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ADXN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$6.75 | +$2.35 |
| Q1 2026 | -$8.20 | -165% |
| Q4 2025 | -$8.92 | -188% |
| Q3 2025 | -$8.85 | -216% |
| Q2 2025 | -$9.10 | -283% |
| Q1 2025 | $12.57 | +$31.74 |
| Q4 2024 | $10.16 | +$30.43 |
| Q3 2024 | $7.61 | +$32.39 |
ADXN is still losing money, but far less than before: $6.75 per share over the past year, against $88.12 at its worst in early 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ADXN on earnings quality, reporting a profit while its opponent remains loss making.
ADXN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.9K | -73% |
| Q4 2025 | $299 | -84% |
| Q3 2025 | $35.8K | -45% |
| Q2 2025 | $43.8K | -68% |
| Q4 2024 | $1.8K | -99% |
| Q3 2024 | $64.8K | -84% |
| Q2 2024 | $138.8K | -82% |
| Q1 2024 | $281.1K | -53% |
ADXN's revenue has slid since its 2020 peak: $11,928 last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -6484% | -4470 points |
| Q1 2026 | -6239% | N/A |
| Q4 2025 | -314219% | -284668 points |
| Q3 2025 | -2342% | -1186 points |
| Q2 2025 | -2015% | -1235 points |
| Q4 2024 | -29551% | -27803 points |
| Q3 2024 | -1156% | -927 points |
| Q2 2024 | -780% | -717 points |
ADXN's operating margin was −6484% last quarter, down 4470 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ADXN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ADXN on profitability, with a higher operating margin.
ADXN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$564.2K | -$58.8K |
| Q1 2026 | -$922K | -$201.2K |
| Q4 2025 | -$732.4K | -$704.1K |
| Q3 2025 | -$641.9K | -$160.5K |
| Q2 2025 | -$505.4K | +$2.8M |
| Q1 2025 | -$720.8K | +$1.9M |
| Q4 2024 | -$28.4K | +$723.1K |
| Q3 2024 | -$481.4K | +$2.2M |
ADXN has burned cash in almost every quarter: −$3M over the past year, against −$2M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ADXN on cash generation, producing positive trailing cash flow while its opponent burns cash.
ADXN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +27K shares |
| 1 year | +90% | +687K shares |
| 3 years | +142% | +852K shares |
| 5 years | +412% | +1.2M shares |
| Available history | +559% | +1.2M shares |
ADXN has 1M diluted shares, up 90% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1,516 |
| Q1 2026 | $3,829 |
| Q4 2025 | — |
| Q3 2025 | $3,306 |
| Q2 2025 | $31,176 |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ADXN spent $8,651 buying back its own shares over the past year, down 72% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over ADXN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ADXN Net Leverage
ADXN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ADXN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.0 | Neutral |
ADXN's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ADXN PE vs Healthcare Sector
| Metric | ADXN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ADXN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ADXN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.37 | 57% above |
| 20 week MA | $4.35 | 22% above |
| 50 week MA | $5.99 | 12% below |
| 100 week MA | $7.17 | 26% below |
| 200 week MA | $9.61 | 45% below |
ADXN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 45% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ADXN on trend strength, trading above more of its moving averages.
ADXN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $226.0 | $483.8 | +114% |
| 2021 | $483.8 | $132.6 | -73% |
| 2022 | $132.6 | $11.2 | -92% |
| 2023 | $11.2 | $6.05 | -46% |
| 2024 | $6.05 | $7.52 | +24% |
| 2025 | $7.52 | $7.99 | +6.3% |
| 2026 YTD | $7.99 | $5.29 | -34% |
ADXN's yearly returns have swung widely, from +114% in 2020 to −92% in 2022. It's down 34% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ADXN on returns for 2026, with the stronger performance.